8-K: Aptose Biosciences Secures Up to $8.5 Million Debt Facility from Hanmi Pharmaceutical for Tuspetinib Development

Aptose Biosciences Inc. has entered into an uncommitted loan agreement for up to US$8.5 million with Hanmi Pharmaceutical Co. Ltd. to fund the continued clinical development of its Tuspetinib (TUS) triple drug frontline therapy for acute myeloid leukemia (AML) and related business operations.

Summary

• Aptose Biosciences Inc. (the Company) has secured an uncommitted, non-revolving loan facility of up to US$8.5 million from Hanmi Pharmaceutical Co. Ltd. (Hanmi).
• The facility can be advanced in one or more tranches, up to a maximum of five advances, with no single advance exceeding US$2,500,000.
• The Facility Availability Period extends until December 31, 2025, after which any unadvanced portion will be permanently cancelled.
• The aggregate principal amount, accrued interest, and fees are repayable in full by August 31, 2028 (the Maturity Date).
• Unpaid principal accrues interest at 6% per annum, with a default interest rate of 9% per annum.
• Proceeds are specifically designated for Tuspetinib (TUS) related business operations, including continued clinical development of a TUS-based triple drug frontline therapy for newly diagnosed acute myeloid leukemia (AML), TUS-related accounts payable, and general corporate purposes related to TUS operations.
• The Company's obligations are secured by a first-ranking security interest over all present and after-acquired personal property of Aptose and its subsidiaries (Aptose Biosciences U.S. Inc. and NuChem Pharmaceuticals Inc.), including TUS inventory, clinical trial data, and the existing License Agreement with Hanmi.
• The Loan Agreement includes customary affirmative and negative covenants, such as compliance with laws, no change of business, no merger, maintenance of corporate existence, insurance, and restrictions on incurring additional loans and guarantees.
• Events of default include non-payment, non-compliance with covenants, misrepresentation, insolvency, creditors' process exceeding US$900,000, material liens exceeding US$900,000, adverse proceedings exceeding US$900,000, cessation of business, unlawfulness, other debt defaults exceeding US$900,000, loss of first priority security, unenforceability of finance documents, and a Material Adverse Effect in the opinion of the Lender.

Sentiment

Score: 6

Explanation: The loan provides crucial funding for clinical development, which is positive for a biotech company. However, the uncommitted nature, broad security over all assets, and stringent covenants, including the subjective 'Material Adverse Effect' clause, introduce significant risks and limitations, tempering the overall positive impact.

Positives

• Secures up to US$8.5 million in funding, providing capital for the continued clinical development of Tuspetinib, a critical asset for the company.
• The funding is specifically allocated to support the 'Triplet Study' in frontline acute myeloid leukemia, indicating continued progress in a key therapeutic area.
• The loan has a defined maturity date of August 31, 2028, providing a clear repayment timeline.

Negatives

• The facility is 'uncommitted' and 'fully discretionary,' meaning Hanmi Pharmaceutical can cancel availability at any time without notice, and advances are not automatically available.
• The loan is secured by a first-ranking security interest over 'all present and after acquired personal property' of Aptose and its subsidiaries, including valuable assets like Tuspetinib clinical trial data and the License Agreement with Hanmi, which is a very broad and restrictive collateralization.
• The interest rate of 6% per annum, with a default rate of 9%, represents a significant cost of capital.
• The agreement contains stringent covenants, including restrictions on incurring other indebtedness, making loans, providing guarantees, disposals of assets outside ordinary course of business, and acquiring new subsidiaries or businesses without Hanmi's prior written consent.
• An 'Event of Default' can be triggered by a 'Material Adverse Effect' in the 'opinion of the Lender, acting reasonably,' which introduces subjective risk.
• Certain portions of the exhibit, including details on the Cash Flow Statement period and bank information, have been redacted for confidentiality.

Risks

• The uncommitted nature of the facility means future advances are not guaranteed and are subject to the sole discretion of Hanmi, potentially impacting the continuity of Tuspetinib development if funds are withheld.
• The broad security interest over all company assets, including intellectual property and clinical data, could severely limit Aptose's ability to secure alternative financing or engage in other strategic transactions.
• Failure to comply with any of the numerous and stringent covenants, or the occurrence of an Insolvency Event, could lead to immediate acceleration of the entire loan and enforcement of security.
• The subjective 'Material Adverse Effect' clause, determined by the Lender's opinion, creates uncertainty and potential for early default declaration.
• Reliance on a single lender (Hanmi) for this critical funding, especially given their existing License Agreement, concentrates financial risk and potentially limits strategic flexibility.

Future Outlook

The proceeds from this loan agreement are primarily intended to fund the continued clinical development of Tuspetinib, specifically for a triple drug frontline therapy to treat newly diagnosed acute myeloid leukemia (AML). This indicates a strategic focus on advancing the 'Triplet Study' and maintaining key resources for these clinical trials.

Management Comments

• William G. Rice, Ph.D., Chairman, President, and Chief Executive Officer of Aptose Biosciences Inc., signed the report on behalf of the registrant.

Industry Context

This debt financing is typical for clinical-stage biotechnology companies like Aptose Biosciences, which often rely on external capital to fund expensive and lengthy drug development programs, particularly clinical trials. The focus on acute myeloid leukemia (AML) highlights a high-need area in oncology. The involvement of Hanmi Pharmaceutical, an existing licensee, suggests a continued strategic partnership, which can be common in biotech where larger pharmaceutical companies invest in or support smaller innovators' pipelines.

Comparison to Industry Standards

• The uncommitted nature of the facility and the lender's sole discretion for advances are more restrictive than typical committed credit facilities often seen with more mature biotech companies or those with commercialized products. This structure places significant control with the lender, Hanmi Pharmaceutical.
• The broad security interest over 'all present and after acquired personal property,' including intellectual property and clinical data, is a stringent term, often indicative of a company with limited alternative financing options or a lender seeking maximum protection. More established biotechs might secure debt against specific assets or have less encompassing liens.
• The 6% interest rate, while not exorbitant, is on the higher side for corporate debt, reflecting the inherent risk associated with clinical-stage drug development and the company's current financial position.
• The inclusion of a 'Material Adverse Effect' clause, where the lender's opinion can trigger an event of default, is a common but powerful provision that grants significant leverage to the lender, similar to terms seen in high-risk venture debt or distressed financing scenarios.

Related Party Transactions

• The loan agreement is with Hanmi Pharmaceutical Co. Ltd., which is also the counterparty to an existing exclusive License Agreement with Aptose Biosciences Inc. (dated November 4, 2021), making this a related party transaction.

Stakeholder Impact

• **Shareholders**: The financing provides a runway for continued clinical development, potentially preserving shareholder value by avoiding immediate dilution from equity raises. However, the stringent terms, broad security, and uncommitted nature of the debt could be a concern, as it increases financial risk and limits future flexibility. The debt also adds leverage to the company's balance sheet.
• **Employees**: Continued funding for Tuspetinib development helps maintain employment stability for personnel involved in the 'Triplet Study' and related operations.
• **Customers/Patients**: Continued development of Tuspetinib could eventually lead to a new treatment option for patients with acute myeloid leukemia.
• **Creditors**: Hanmi Pharmaceutical Co. Ltd. becomes a primary secured creditor with a first-ranking security interest over virtually all of Aptose's assets, including intellectual property, which significantly enhances their position relative to other potential creditors.

Next Steps

• Aptose Biosciences will continue the clinical development of its Tuspetinib (TUS) based triple drug frontline therapy for newly diagnosed acute myeloid leukemia (AML) using the loan proceeds.
• The Company will maintain key resources necessary to conduct the clinical trials in respect of the Triplet Study.
• The Company will need to provide a Notice of Advance for each subsequent draw on the facility, along with updated Cash Flow Statements if requested by the Lender.
• The Company must comply with all affirmative and negative covenants outlined in the Loan Agreement until the maturity date of August 31, 2028.

Key Dates

Recommendation

Keywords

Aptose Biosciences, Hanmi Pharmaceutical, Loan Agreement, Debt Facility, Tuspetinib, AML, Acute Myeloid Leukemia, Clinical Development, Biotechnology, Pharmaceuticals, SEC Filing, 8-K, Corporate Finance, Secured Debt, Clinical Trials